Critical Path Institute (C-Path) hosted the Global Impact Conference 2026 featuring three days of high-impact dialogue and collaboration focused on accelerating better treatments for patients worldwide.
Public source
Publisher name
Public post
Be part of the global conversation shaping the future of drug development. The Critical Path Institute’s Global Impact Conference 2026 brings together regulators, indust…
Company
Critical Path Institute (C-Path)
Advancing Drug Development. Improving Lives. Together.
- Industry
- Research Services
- Company size
- 51–200 employees
About Critical Path Institute (C-Path)
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
See moreLatest activity
Latest activity from Critical Path Institute (C-Path)
7 signals
Research & Knowledge
Critical Path Institute (C-Path) researchers are closer than ever to developing the first targeted treatments for Autosomal Dominant Tubulointerstitial Kidney Disease caused by UMOD and MUC1 gene variants.
Presence & Recognition
Critical Path Institute (C-Path) hosted the Global Impact Conference 2026 featuring three days of high-impact dialogue and collaboration focused on accelerating better treatments for patients worldwide.
Presence & Recognition
Critical Path Institute (C-Path) released the newest episode of the Critical Path Institute Podcast exploring collaboration between patients, researchers, regulators, and drug developers for neuromuscular drug development.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
P3 Research
P3 Research is attending the 2026 C-PATH Global Impact Conference in Washington, D.C. from September 15 to 16.
Presence & Recognition
Navitas Life Sciences
Navitas Life Sciences participated in the pharmaREADY User Group 2026 session to share real-world experiences, explore regulatory requirements, and discuss the industry.
Presence & Recognition
CISCRP
CISCRP representative Kimbra Edwards, PhD is attending Clinical Data Disclosure & Transparency 2026 panel discussion on Patient and Site Perspective: Bridging Communication Gaps.
Presence & Recognition
Oxford Global
Oxford Global is hosting Drug Discovery US 2026 at Discovery & Development US in San Diego from October 12 to 13, 2026, featuring over 1,000 scientists, R&D leaders, and technologists.
Presence & Recognition
Veristat